U.S. Law Firms Ride Into Court in Battle with Novo Nordisk

Legal Challenges and Investor Concerns Surround Novo Nordisk

In the world of healthcare, even small mistakes can carry significant consequences. For pharmaceutical giant Novo Nordisk (NVO), a growing number of legal challenges have begun to raise concerns among investors. A coalition of top-tier securities law firms is now actively seeking to represent affected shareholders in potential lawsuits, aiming to recover losses from the company’s alleged missteps.

Over 20 leading U.S. law firms have issued press releases in recent weeks, urging NVO investors to consider their options. These firms are particularly interested in those who purchased or acquired shares between May 7th and July 28, 2025. One such firm, Faruqi & Faruqi, has encouraged affected investors to reach out and discuss their legal avenues. Similarly, Glancy Prongay & Murray has invited investors to join a securities fraud lawsuit, with a deadline set for September 30, 2025.

The complaints center around allegations that Novo Nordisk failed to disclose critical information regarding its handling of GLP-1 compounding treatments. Specifically, the company is accused of downplaying the importance of the personalization exception during this period. Additionally, the lawsuit claims that the company overestimated its ability to transition patients from compounded treatments, which may have misled investors about its market potential.

Prosecutors argue that these statements were misleading and could have significantly impacted investor decisions. Despite these legal challenges, NVO stock has remained relatively stable, trading within a narrow range. However, the stock ended the week slightly lower, with further declines observed in after-hours trading, indicating possible continued pressure in the near term.

Financial Performance and Future Outlook

Despite the legal turmoil, Novo Nordisk's financial results for the first half of 2025 show strong performance. Operating profit surged by 25% to DKK 72.2 billion, with U.S. sales increasing by 16%. Sales in Diabetes and Obesity care rose by 16% to DKK 145.4 billion, driven by a remarkable 56% increase in obesity treatments and steady growth in GLP-1 diabetes drugs. Rare disease sales also saw a 14% rise, and management is forecasting 2025 sales growth of 8–14%, with operating profit expected to grow by 10–16%.

These results suggest that the company is still performing well in key areas, despite the ongoing legal issues. Future plans include the commercialization of Ozempic for peripheral arterial disease and the advancement of amycretin into Phase III clinical trials. These developments could be significant under the leadership of new CEO Maziar Mike Doustdar.

However, the company has also lowered its full-year outlook due to challenges in the U.S. market and decreased free cash flow. Free cash flow for the first six months of 2025 was DKK 33.6 billion, compared to DKK 41.3 billion in 2024, primarily due to increased capital expenditures.

Analyst Perspectives and Investment Considerations

Wall Street analysts remain cautiously optimistic about NVO, despite the various risks associated with the stock. Among the seven analysts rating the stock, three are bullish, while four are neutral. There is no visible bearish sentiment at this time. The stock price target is currently $67.71 as of the next market open, with some estimates reaching as high as $90. The lowest target, from Evan Seigerman of BMO Capital, is $50 per share.

The recent leadership change, with Maziar Mike Doustdar taking over as CEO, adds another layer of complexity. Helge Lund, the board chair, emphasized the need for speed and ambition as the company navigates its future. While there are opportunities ahead, including expanding Ozempic’s use and advancing amycretin, challenges remain, including ongoing legal issues and a reduced full-year outlook.

Reputational Risks and Market Sentiment

One of the most pressing concerns for NVO is its reputation. Since 2022, the company has acknowledged that its Ozempic medication may cause serious gastrointestinal disorders and severe side effects, including pancreatitis, acute kidney injury, and thyroid cancer. If consumer confidence in NVO’s products continues to decline, the reputational damage could outweigh any legal penalties.

For now, NVO stock remains a complex investment choice. It is a mix of strong financial performance, potential for future growth, and ongoing legal and reputational risks. Investors must weigh these factors carefully as they decide whether to hold, buy, or sell the stock.